BUY

It reports Monday. They've had a great quarter and the CEO has gotten control of things. It pays a 6.6% dividend plus actual growth.

BUY

It reports Monday. Has been strong despite the Fed's rate hikes.

COMMENT

It reports Monday. It grows by acquiring that could buy US Steel.

BUY

It reports Tuesday. It's the second-cheapest S&P stock that isn't a bank. Are buying back a monster amount of shares. Stay long.

BUY

It reports Tuesday. Has major upside. The CEO has steered a beautiful break up. GE is now GE AEROSPACE.

HOLD

It reports Tuesday. It has rebounded well from bottoming after issuing a recall. Shares could stall here, unless they announce something big. A good stock.

COMMENT

This could be the start of a major run in the stock, and their rebound is real. He'd buy before and after their report on Tuesday.

BUY

It reports Tuesday. It's a beat-and-raise machine, driven by subscription revenues. Loves this stick revenue.

WATCH

It reports Tuesday. The last quarter has seen only bad news, but maybe Musk can pull a rabbit out of this hat and it better not be self-driving cars. There's a lot on the line for Tesla. He give Musk the benefit of the doubt.

COMMENT

It reports Wednesday. Nothing but bad news lately. They must announce something new; it can't be business as usual, like announcing a succession plan.

WAIT

 It reports Wednesday. They have a lot of levers to push. Zuckerberg doesn't have to pull a rabbit out of a hat, just talking about earnings and forecasts. Wait. Their quarter could be like Netflix's where the quarter was good, but shares fell anyway.

BUY

It reports Wednesday. They keep putting up great numbers. Are offering generative AI to their customers and showing them how AI benefits their bottom lines.

BUY

It reports Wednesday. They've integrated robots into their operations, have a good point-of-sale and have the best menu with real value. They own their stores and it's not a franchise model. Average volumes per store keep rising.

WAIT

It reports Thursday. Wait till the conference call before pulling the trigger. Also, shares have been on a scorching run leading up to earnings and may need a breather.

BUY

It reports Thursday. He expects them to announce new drug applications, the anti-cancer portfolio and their acquisitions.